ProCE Banner Activity

NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer

Conference Coverage
Slideset

The randomized phase II NORPACT-1 trial showed no overall survival improvement with a short course of neoadjuvant FOLFIRINOX vs standard upfront surgery among patients with resectable pancreatic head cancer.

Released: June 04, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen